Business Description
Bora Pharmaceuticals Co Ltd
ISIN : US09952D1000
Share Class Description:
BORAY: ADRTotal Employee Number:
94Description
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.39 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 1.44 | |||||
Debt-to-EBITDA | 5.02 | |||||
Interest Coverage | 6.22 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.84 | |||||
Beneish M-Score | -2.38 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.5 | |||||
3-Year EBITDA Growth Rate | 38 | |||||
3-Year EPS without NRI Growth Rate | 41.8 | |||||
3-Year FCF Growth Rate | 19 | |||||
3-Year Book Growth Rate | 46.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 30.85 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 19.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.3 | |||||
Quick Ratio | 1.07 | |||||
Cash Ratio | 0.45 | |||||
Days Inventory | 110.36 | |||||
Days Sales Outstanding | 161.08 | |||||
Days Payable | 27.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.3 | |||||
3-Year Dividend Growth Rate | 78.8 | |||||
Forward Dividend Yield % | 2.3 | |||||
5-Year Yield-on-Cost % | 48.25 | |||||
3-Year Average Share Buyback Ratio | -2.8 | |||||
Shareholder Yield % | 0.46 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 39.97 | |||||
Operating Margin % | 15.42 | |||||
Net Margin % | 7.91 | |||||
EBITDA Margin % | 22.24 | |||||
FCF Margin % | 10 | |||||
OCF Margin % | 15.95 | |||||
ROE % | 10.94 | |||||
ROA % | 3.4 | |||||
ROIC % | 5.81 | |||||
3-Year ROIIC % | 6.78 | |||||
ROC (Joel Greenblatt) % | 20.29 | |||||
ROCE % | 10.4 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 7.1 | |||||
Forward PE Ratio | 4.21 | |||||
PE Ratio without NRI | 6.08 | |||||
Shiller PE Ratio | 39.14 | |||||
Price-to-Owner-Earnings | 42.01 | |||||
PEG Ratio | 0.12 | |||||
PS Ratio | 3.32 | |||||
PB Ratio | 4.22 | |||||
Price-to-Tangible-Book | 9.45 | |||||
Price-to-Free-Cash-Flow | 33.5 | |||||
Price-to-Operating-Cash-Flow | 20.93 | |||||
EV-to-EBIT | 8.18 | |||||
EV-to-EBITDA | 6.08 | |||||
EV-to-Revenue | 1.35 | |||||
EV-to-FCF | 13.55 | |||||
Price-to-GF-Value | 0.59 | |||||
Price-to-Projected-FCF | 1.78 | |||||
Price-to-DCF (Earnings Based) | 0.19 | |||||
Price-to-DCF (FCF Based) | 0.18 | |||||
Price-to-Median-PS-Value | 0.8 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.43 | |||||
Price-to-Graham-Number | 3.86 | |||||
Earnings Yield (Greenblatt) % | 12.22 | |||||
FCF Yield % | 17.89 | |||||
Forward Rate of Return (Yacktman) % | 23.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BORAY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Bora Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 625.098 | ||
| EPS (TTM) ($) | 0.386 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 74.62 | ||
| 14-Day ATR ($) | 0.028889 | ||
| 20-Day SMA ($) | 2.5425 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 2.39 - 2.74 | ||
| Shares Outstanding (Mil) | 127.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bora Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bora Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| USD 0.062923 Cash Dividend | 2026-07-31 | 2.59 (+0.00%) |
Show
Entries
Bora Pharmaceuticals Co Ltd Frequently Asked Questions
What is Bora Pharmaceuticals Co Ltd(BORAY)'s stock price today?
The current price of BORAY is $2.74. The 52 week high of BORAY is $2.74 and 52 week low is $2.39.
When is next earnings date of Bora Pharmaceuticals Co Ltd(BORAY)?
The next earnings date of Bora Pharmaceuticals Co Ltd(BORAY) is .
Does Bora Pharmaceuticals Co Ltd(BORAY) pay dividends? If so, how much?
The Dividend Yield % of Bora Pharmaceuticals Co Ltd(BORAY) is 2.3% (As of Today), Highest Dividend Payout Ratio of Bora Pharmaceuticals Co Ltd(BORAY) was 1.4. The lowest was 0.08. And the median was 0.36. The Forward Dividend Yield % of Bora Pharmaceuticals Co Ltd(BORAY) is 2.3%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Bora Pharmaceuticals Co Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers